HRP20201285T1 - Reagensi sirp-alfa visokog afiniteta - Google Patents
Reagensi sirp-alfa visokog afiniteta Download PDFInfo
- Publication number
- HRP20201285T1 HRP20201285T1 HRP20201285TT HRP20201285T HRP20201285T1 HR P20201285 T1 HRP20201285 T1 HR P20201285T1 HR P20201285T T HRP20201285T T HR P20201285TT HR P20201285 T HRP20201285 T HR P20201285T HR P20201285 T1 HRP20201285 T1 HR P20201285T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- sirpα
- affinity
- amino acid
- polypeptide according
- Prior art date
Links
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 38
- 102000004196 processed proteins & peptides Human genes 0.000 claims 38
- 108090000765 processed proteins & peptides Proteins 0.000 claims 38
- 102200067664 rs397507595 Human genes 0.000 claims 19
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 18
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 18
- 102200145334 rs2274084 Human genes 0.000 claims 16
- 102220474111 Inorganic pyrophosphatase 2, mitochondrial_S66G_mutation Human genes 0.000 claims 15
- 102220585510 D site-binding protein_S66T_mutation Human genes 0.000 claims 13
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 claims 13
- 102220266399 rs1555186817 Human genes 0.000 claims 13
- 102200121507 rs587777568 Human genes 0.000 claims 13
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 claims 12
- 102220054711 rs115275492 Human genes 0.000 claims 12
- 102220042944 rs117812409 Human genes 0.000 claims 11
- 102220074214 rs373822815 Human genes 0.000 claims 11
- 230000004048 modification Effects 0.000 claims 10
- 238000012986 modification Methods 0.000 claims 10
- 102220481372 G-protein coupled receptor family C group 6 member A_E47K_mutation Human genes 0.000 claims 9
- 150000001413 amino acids Chemical class 0.000 claims 9
- 102220471946 Axin interactor, dorsalization-associated protein_H56R_mutation Human genes 0.000 claims 8
- 102220503704 Cyclin-dependent kinase 8_V27L_mutation Human genes 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 102220024927 rs199472833 Human genes 0.000 claims 8
- 102220291891 rs567483147 Human genes 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 102200097283 rs199472833 Human genes 0.000 claims 7
- 102220542110 Feline leukemia virus subgroup C receptor-related protein 2_F94V_mutation Human genes 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 102200025792 rs179363886 Human genes 0.000 claims 5
- 238000000926 separation method Methods 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 102200153332 rs116840818 Human genes 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 102000044459 human CD47 Human genes 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (25)
1. Polipeptid SIRPα visokog afiniteta, naznačen time, da sadrži najmanje jednu i ne više od 15 aminokiselinskih modifikacija unutar d1 domene ljudske sekvence SIRPα divljeg tipa, pri čemu su modifikacije učinjene na ostacima koji odgovaraju ostacima odabranima iz skupine koja se sastoji od sljedećih: L4, V6, A21, V27, I31, E47, K53, E54, H56, V63, S66, K68, V92, F94 i F103 od SEQ ID NO:1, gdje aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47 u odnosu na afinitet ljudskog polipeptida SIRPα divljeg tipa i pritom polipeptidu SIRPα visokog afiniteta nedostaje domena transmembrane SIRPα.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid SIRPα visokog afiniteta ima KD od najmanje 1 x 10-9 M za CD47.
3. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid SIRPα visokog afiniteta ima KD od najmanje 1 x 10-8 M za CD47.
4. Polipeptid prema bio kojem od patentnih zahtjeva 1 do 3, naznačen time, da
(i) se polipeptid sastoji od cijele ili od dijela d1 domene SIRPα, i
(ii) polipeptid sadrži aminokiselinske sekvence od SIRPα izvan d1 domene.
5. Polipeptid prema patentnom zahtjevu 1, naznačen time, da sadrži najmanje jednu aminokiselinsku modifikaciju odabranu od sljedećih: (1) L4V; L4I; (2) V6I; V6L; (3) A21V; (4) V27I; V27L; (5) I31T; I31S; I31F; (6) E47V; E47L; (7) K53R; (8) E54Q; (9) H56P; H56R; (10) S66T; S66G; (11) K68R; (12)V92I; (13) F94L; F94V; (14) V63I; i (15) F103V.
6. Polipeptid prema patentnom zahtjevu 5, naznačen time, da sadrži aminokiselinske modifikacije odabrane od sljedećih:
i. V6I; V27I; I31F; E47V; K53R; E54Q; H56P; S66T; i V92I;
ii. V27I ili V27L; K53R; S66T ili S66G; K68R; i F103V;
iii. L4V ili L4I; V27I ili V27L; E47V ili E47L; K53R; E54Q; S66T ili S66G; K68R; V92I; i F103V;
iv. L4V ili L4I; V6I ili V6L; A21V; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; H56P ili H56R; S66T ili S66G; K68R; i F94L ili F94V;
v. V6I ili V6L; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; E54Q; H56P ili H56R; S66T ili S66G; V92I; i F94L ili F94V;
vi. L4V ili L4I; A21V; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; E54Q; H56P ili H56R; S66T ili S66G; F94L ili F94V; i F103V;
vii. L4V ili L4I; V6I ili V6L; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; H56P ili H56R; S66T ili S66G; K68R; V92I, i F94L ili F94V;
viii. L4V ili L4I; V6I ili V6L; I31T, I31S ili I31F; E47V ili E47L; K53R; H56P ili H56R; S66T ili S66G; V92I; i F103V;
ix. V6I; V27I; I31F; E47L; K53R; E54Q; H56P; i S66T;
x. L4V; V6I; V27I; I31F; E47V; K53R; E54Q; H56P; V63I; S66T; K68R; i V92I;
xi. V6I; V27I; I31T; E47V; K53R; E54Q; H56P; S66G; K68R; V92I; i F103V;
xii. V27I; K53R; S66T; S66G; K68R; F103V;
xiii. L4V; V27L; E47V; K53R; E54Q; S66G; K68R; V92I;
xiv. L4V; V6I; A21V; V27I; I31T; E47L; K53R; H56P; S66T; K68R; F94L;
xv. V6I; V27I; I31S; I31F; E47V; K53R; E54Q; H56P; S66G; V92I; F94L;
xvi. L4I; A21V; V27I; I31F; E47V; K53R; E54Q; H56R; S66G; F94V; F103V;
xvii. L4V; V6I; V27I; I31F; E47V; K53R; H56R; S66G; K68R; V92I; F94L; ili
xviii. L4V; V6L; I31F; E47V; K53R; H56P; S66G; V92I; F103V.
7. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid SIRPα visokog afiniteta sadrži aminokiselinsku sekvencu prikazanu u bilo kojem od SEQ ID NO: 3-6, 8-10 i 37-39.
8. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO: 10.
9. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da je staljen na Fc sekvencu imunoglobulina.
10. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je polipeptid SIRPα visokog afiniteta multimer.
11. Terapeutska formulacija, naznačena time, da obuhvaća polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 10.
12. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da polipeptid dodatno sadrži oznaku koja se može detektirati.
13. Formulacija prema patentnom zahtjevu 11, naznačena time, da se upotrebljava u postupku liječenja raka, pri čemu postupak obuhvaća dovođenje u doticaj in vivo stanice koja eksprimira CD47 s formulacijom.
14. Formulacija za uporabu prema patentnom zahtjevu 13, naznačena time, da nadalje obuhvaća dovođenje u doticaj navedene stanice s protutijelom koje je specifično za tumor.
15. Formulacija za uporabu prema patentnom zahtjevu 13, naznačena time, da stanica koja eksprimira CD47 jest stanica raka.
16. Formulacija prema patentnom zahtjevu 11, naznačena time, da se upotrebljava u postupku liječenja upalne bolesti ili autoimune bolesti, pri čemu postupak obuhvaća davanje formulacije u spoju s terapeutskim protutijelom.
17. Postupak in vitro za modulaciju fagocitoze stanice koja eksprimira CD47, naznačen time, da obuhvaća dovođenje u doticaj in vitro navedene stanice s formulacijom u skladu s patentnim zahtjevom 11.
18. Polipeptid prema patentnom zahtjevu 12, naznačen time, da se upotrebljava u postupku prikazivanja tumora, pri čemu postupak obuhvaća dovođenje u doticaj stanica raka s polipeptidom.
19. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je polipeptid SIRPα visokog afiniteta monomer.
20. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 10 puta.
21. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 20 puta.
22. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 50 puta.
23. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 100 puta.
24. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 500 puta.
25. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da CD47 je ljudski CD47.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261587247P | 2012-01-17 | 2012-01-17 | |
| EP13738232.1A EP2804617B9 (en) | 2012-01-17 | 2013-01-17 | High affinity sirp-alpha reagents |
| PCT/US2013/021937 WO2013109752A1 (en) | 2012-01-17 | 2013-01-17 | High affinity sirp-alpha reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201285T1 true HRP20201285T1 (hr) | 2020-11-13 |
Family
ID=48799653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201285TT HRP20201285T1 (hr) | 2012-01-17 | 2020-08-17 | Reagensi sirp-alfa visokog afiniteta |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9944911B2 (hr) |
| EP (2) | EP3766511A1 (hr) |
| JP (5) | JP6460796B2 (hr) |
| CN (2) | CN107880100A (hr) |
| AU (1) | AU2013209736C1 (hr) |
| CA (1) | CA2861307C (hr) |
| CY (1) | CY1123419T1 (hr) |
| DK (1) | DK2804617T3 (hr) |
| ES (1) | ES2816647T3 (hr) |
| HK (2) | HK1253217A1 (hr) |
| HR (1) | HRP20201285T1 (hr) |
| HU (1) | HUE050875T2 (hr) |
| LT (1) | LT2804617T (hr) |
| PL (1) | PL2804617T3 (hr) |
| PT (1) | PT2804617T (hr) |
| RS (1) | RS60606B1 (hr) |
| SI (1) | SI2804617T1 (hr) |
| WO (1) | WO2013109752A1 (hr) |
Families Citing this family (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60606B1 (sr) * | 2012-01-17 | 2020-08-31 | Univ Leland Stanford Junior | Reagensi sirp-alfa visokog affiniteta |
| KR102338833B1 (ko) | 2012-02-06 | 2021-12-13 | 인히브릭스, 인크. | Cd47 항체 및 그 사용 방법 |
| PT3575326T (pt) * | 2012-12-17 | 2022-05-30 | Pf Argentum Ip Holdings Llc | Tratamento de células de doença cd47+ com fusões sirp alfa-fc |
| PT2970493T (pt) | 2013-03-15 | 2019-06-27 | Univ Leland Stanford Junior | Métodos para obter doses terapeuticamente eficazes de agentes anti-cd47 |
| CA2910466A1 (en) * | 2013-04-29 | 2014-11-06 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-cd47 agents to enhance immunization |
| WO2015041987A1 (en) * | 2013-09-18 | 2015-03-26 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| EP3131917B1 (en) | 2014-04-18 | 2020-06-17 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd99 |
| HUE050406T2 (hu) | 2014-08-08 | 2020-12-28 | Univ Leland Stanford Junior | Nagy affinitású PD-1 hatóanyag és alkalmazási módszerek |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| CN106535914B (zh) * | 2014-08-08 | 2021-08-27 | Alx 肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| EP3188758B1 (en) * | 2014-08-08 | 2023-10-04 | The Board of Trustees of the Leland Stanford Junior University | Sirp alpha-antibody fusion proteins |
| CA2956126A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| CA3229961A1 (en) | 2014-08-26 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
| US10822411B2 (en) | 2014-09-15 | 2020-11-03 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting aneurysm disease by modulating phagocytosis pathways |
| US10316094B2 (en) | 2014-10-24 | 2019-06-11 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| SG11201704058TA (en) * | 2014-11-18 | 2017-06-29 | Janssen Pharmaceutica Nv | Cd47 antibodies, methods, and uses |
| EA037654B1 (ru) * | 2014-12-30 | 2021-04-27 | Селджин Корпорейшн | Анти-cd47-антитела и их применения |
| EP3261671B1 (en) | 2015-02-27 | 2020-10-21 | The Board of Trustees of the Leland Stanford Junior University | Combination therapy for treatment of atherosclerosis |
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| US10358472B2 (en) | 2015-05-06 | 2019-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity CD47 analogs |
| WO2016187226A1 (en) | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| RS62151B1 (sr) * | 2015-08-07 | 2021-08-31 | Alx Oncology Inc | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu |
| BR102016018074A2 (pt) | 2015-08-07 | 2021-11-16 | ALX Oncology Inc. | Construção variante de sirp-alfa, seu método de preparação e seus usos, molécula de ácido nucleico, vetor, célula hospedeira, e composição farmacêutica |
| PT3341015T (pt) | 2015-08-26 | 2021-10-12 | Univ Leland Stanford Junior | Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária |
| KR20180083895A (ko) | 2015-12-11 | 2018-07-23 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Cd47 및 egfr의 이중 표적화를 이용한 암의 치료 |
| KR102472087B1 (ko) | 2016-01-11 | 2022-11-29 | 포티 세븐, 인코포레이티드 | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 |
| IL262251B2 (en) | 2016-04-14 | 2023-09-01 | Ose Immunotherapeutics | New anti-syrap antibodies and their medical applications |
| EP3442578B1 (en) | 2016-04-15 | 2022-02-09 | The Board of Trustees of the Leland Stanford Junior University | Methods for determining and achieving therapeutically effective doses of anti-cd47 agents in treatment of cancer |
| US11649284B2 (en) | 2016-04-18 | 2023-05-16 | Baylor College Of Medicine | Cancer gene therapy targeting CD47 |
| US10934355B2 (en) * | 2016-04-29 | 2021-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| US10148939B2 (en) | 2016-07-19 | 2018-12-04 | Gopro, Inc. | Mapping of spherical image data into rectangular faces for transport and decoding across networks |
| US10995152B2 (en) * | 2016-10-26 | 2021-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| CA3042581A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| EP3534965A4 (en) | 2016-11-03 | 2020-06-24 | Trillium Therapeutics Inc. | IMPROVEMENTS IN CD47 BLOCKADERAPY THROUGH HDAC INHIBITORS |
| KR102129067B1 (ko) * | 2016-12-29 | 2020-07-08 | 한국과학기술연구원 | 신규 엑소좀 계열 항암제 |
| WO2018127917A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-41bbl fusion protein and methods of use thereof |
| AU2018205890B2 (en) | 2017-01-05 | 2021-09-02 | Kahr Medical Ltd. | A sirpalpha-41BBL fusion protein and methods of use thereof |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| CA3049579A1 (en) | 2017-01-06 | 2018-07-12 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| KR20190109440A (ko) | 2017-01-30 | 2019-09-25 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 줄기 세포 이식을 위한 비-유전독성 컨디셔닝 레지멘 |
| CA3053392A1 (en) * | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of cd47 blockade |
| US11078272B2 (en) | 2017-03-09 | 2021-08-03 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of CD47 pathway |
| SI3642242T1 (sl) | 2017-06-21 | 2024-05-31 | The Board of Trustees of the Leland Stanford Junior University Office of the General Counsel | Parametri odmerjanja za terapije, ki ciljajo na CD47, za hematološke malignosti |
| EP3651782A1 (en) | 2017-07-12 | 2020-05-20 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| US11401329B2 (en) | 2017-08-02 | 2022-08-02 | Phanes Therapeutics, Inc. | Anti-CD47 antibodies and uses thereof |
| CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
| WO2019061012A1 (zh) * | 2017-09-26 | 2019-04-04 | 南京凯地生物科技有限公司 | 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用 |
| WO2019073080A1 (en) | 2017-10-13 | 2019-04-18 | Ose Immunotherapeutics | ANTI-SIRPA MODIFIED ANTIBODIES AND USES THEREOF |
| KR20200068730A (ko) | 2017-10-18 | 2020-06-15 | 포티 세븐, 인코포레이티드 | 항-cd47 작용제-기초된 난소암 요법 |
| CA3080640C (en) | 2017-11-06 | 2024-04-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
| KR20200091901A (ko) | 2017-12-01 | 2020-07-31 | 시애틀 지네틱스, 인크. | 암을 치료하기 위한 cd47 항체 및 이의 용도 |
| WO2019109357A1 (zh) * | 2017-12-08 | 2019-06-13 | 杭州翰思生物医药有限公司 | 抗pd-1/cd47的双特异性抗体及其应用 |
| CN109971716B (zh) * | 2017-12-28 | 2023-08-01 | 上海细胞治疗研究院 | 自分泌cd47抗体的egfr特异性car-t细胞及其用途 |
| PL3752190T3 (pl) | 2018-02-12 | 2022-11-07 | Forty Seven, Inc. | „schemat przeciwnowotworowy z wykorzystaniem przeciwciał anty-cd47 i anty-cd20 |
| CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
| EP3765080A4 (en) * | 2018-03-13 | 2022-03-16 | Trillium Therapeutics Inc. | IMPROVEMENTS IN THERAPY FOR CD47 BLOCKADE BY EGFR ANTIBODIES |
| BR112020017709A2 (pt) | 2018-03-13 | 2020-12-29 | Ose Immunotherapeutics | Anticorpo anti-sirpa humana, fragmento de ligação a antígeno do mesmo ou anticorpo modificado do mesmo, composição farmacêutica, uso de um polipeptídeo, métodos para preparar um anticorpo anti-sirpa humana v1, para aumentar a apresentação cruzada de um antígeno e para avaliar a probabilidade de eficácia de um tratamento, método in vitro ou ex vivo para avaliar a probabilidade de eficácia de um tratamento, e, combinação de compostos |
| CN108872569A (zh) * | 2018-06-19 | 2018-11-23 | 浠思（上海）生物技术有限公司 | 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法 |
| MX2020013068A (es) | 2018-07-10 | 2021-03-02 | Univ Kobe Nat Univ Corp | Anticuerpo anti proteína reguladora de señales alfa sirpalfana. |
| KR102129522B1 (ko) * | 2018-07-26 | 2020-07-02 | 한국과학기술연구원 | 암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물 |
| JP2021534769A (ja) | 2018-08-31 | 2021-12-16 | エーエルエックス オンコロジー インコーポレイテッド | デコイポリペプチド |
| AU2019336345A1 (en) * | 2018-09-04 | 2021-04-15 | Pfizer Inc. | CD47 blockade with parp inhibition for disease treatment |
| CN109306017B (zh) * | 2018-10-12 | 2021-02-09 | 倍而达药业（苏州）有限公司 | 一种基于SIRP-αD1突变体制备的重组蛋白及应用 |
| US20220002385A1 (en) * | 2018-11-07 | 2022-01-06 | Daiichi Sankyo Company, Limited | Method of improving blood kinetics of peptide |
| AU2019390394B2 (en) | 2018-11-28 | 2023-11-30 | Forty Seven, Inc. | Genetically modified HSPCs resistant to ablation regime |
| US20220289821A1 (en) * | 2018-11-29 | 2022-09-15 | Trillium Therapeutics Inc | Biomarkers for cd47 blockade therapy |
| EP3898676A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| WO2020257196A1 (en) * | 2019-06-17 | 2020-12-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating infections by blocking pathogen mimics of cd47 |
| KR20220047277A (ko) | 2019-07-16 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | Hiv 백신, 및 이의 제조 및 사용 방법 |
| CN114555123B (zh) | 2019-10-18 | 2024-04-02 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
| AU2020374947A1 (en) | 2019-10-31 | 2022-03-31 | Forty Seven, Inc. | Anti-CD47 and anti-CD20 based treatment of blood cancer |
| KR20220107223A (ko) | 2019-11-27 | 2022-08-02 | 알렉소 온콜로지 인크. | 암 치료를 위한 병용 요법 |
| US11845723B2 (en) | 2019-12-24 | 2023-12-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| TWI832035B (zh) | 2020-02-14 | 2024-02-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| EP4127139A1 (en) | 2020-03-27 | 2023-02-08 | Mendus B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| US20220401516A1 (en) | 2020-06-01 | 2022-12-22 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| CN114057888A (zh) * | 2020-07-30 | 2022-02-18 | 三生国健药业（上海）股份有限公司 | 一种SIRPα-Fc融合蛋白 |
| KR102557016B1 (ko) * | 2020-09-22 | 2023-07-20 | 비피진 주식회사 | 암 치료를 위한 cd47 바인더 및 리포좀 복합체 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| EP4256336A1 (en) | 2020-12-06 | 2023-10-11 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| JP2024510989A (ja) | 2021-03-12 | 2024-03-12 | メンドゥス・ベスローテン・フェンノートシャップ | ワクチン接種方法及びｃｄ４７遮断薬の使用 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| WO2022229818A1 (en) | 2021-04-27 | 2022-11-03 | Pf Argentum Ip Holdings Llc | Enhancement of cd47 blockade therapy with dhfr inhibitors |
| BR112023022774A2 (pt) | 2021-05-13 | 2024-01-02 | Alx Oncology Inc | Terapias de combinação para tratamento de câncer |
| US11976072B2 (en) | 2021-06-23 | 2024-05-07 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023003331A1 (en) * | 2021-07-19 | 2023-01-26 | Yuhan Corporation | Sirp-alpha variants and use thereof |
| CN118139858A (zh) | 2021-10-28 | 2024-06-04 | 吉利德科学公司 | 吡地嗪-3(2h)-酮衍生物 |
| KR20240097895A (ko) | 2021-10-29 | 2024-06-27 | 길리애드 사이언시즈, 인코포레이티드 | Cd73 화합물 |
| WO2023073580A1 (en) | 2021-10-29 | 2023-05-04 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| CN118139874A (zh) * | 2021-11-01 | 2024-06-04 | 山东先声生物制药有限公司 | SIRPa突变体及其应用 |
| WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| AU2022421675A1 (en) * | 2021-12-21 | 2024-05-02 | Fbd Biologics Limited | ENGINEERED SIRPα VARIANTS AND METHODS OF USE THEREOF |
| CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023121890A1 (en) * | 2021-12-23 | 2023-06-29 | Fbd Biologics Limited | Cd47/4-1bb-targeting protein complex and methods of use thereof |
| AU2022435471A1 (en) * | 2022-01-18 | 2024-05-30 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| AU2023233730A1 (en) | 2022-03-17 | 2024-09-26 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| AU2023240361A1 (en) | 2022-03-24 | 2024-10-03 | Bitterroot Bio, Inc. | Sirp-alpha fusion polypeptides with modified fc domains |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023183890A1 (en) | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2023228044A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Dosing regimens of sirp alpha fusion proteins for treatment of cancer |
| WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024015634A2 (en) * | 2022-07-15 | 2024-01-18 | Nutcracker Therapeutics, Inc. | Mrna therapies including sirp-alpha |
| WO2024040151A1 (en) | 2022-08-18 | 2024-02-22 | Pfizer Inc. | Sirp alpha fusion protein and anti-cd38 antibody combination therapies |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
| WO2024124107A2 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-cd20 / anti-cd3 bispecific antibody combination therapy |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024193635A1 (en) * | 2023-03-22 | 2024-09-26 | Wangzhi LI | Sirp variants and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541615B1 (en) * | 1996-11-15 | 2003-04-01 | Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. | SIRP proteins and uses thereof |
| JP2003502062A (ja) * | 1999-06-11 | 2003-01-21 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | ４９個のヒト分泌タンパク質 |
| US7691970B2 (en) * | 2003-08-25 | 2010-04-06 | Pieris Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| CA2702217A1 (en) * | 2007-10-11 | 2009-04-16 | Jayne Danska | Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor |
| JP2012512640A (ja) * | 2008-12-19 | 2012-06-07 | ノバルティス アーゲー | 自己免疫および炎症性障害の処置に使用するための可溶性ポリペプチド |
| PL2995315T3 (pl) * | 2009-05-15 | 2024-04-22 | University Health Network | Kompozycje i sposoby leczenia nowotworów hematologicznych celujące w oddziaływanie sirp alfa-cd47 |
| RS60606B1 (sr) * | 2012-01-17 | 2020-08-31 | Univ Leland Stanford Junior | Reagensi sirp-alfa visokog affiniteta |
| CA3229961A1 (en) * | 2014-08-26 | 2016-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling |
| PT3341015T (pt) * | 2015-08-26 | 2021-10-12 | Univ Leland Stanford Junior | Depleção incrementada de células-alvo com bloqueio de cd47 e um agonista de costimulação imunitária |
| KR102024554B1 (ko) * | 2018-02-26 | 2019-09-24 | 엘지전자 주식회사 | 유도 가열 장치 및 유도 가열 장치의 제어 방법 |
-
2013
- 2013-01-17 RS RS20200928A patent/RS60606B1/sr unknown
- 2013-01-17 EP EP20180952.2A patent/EP3766511A1/en active Pending
- 2013-01-17 US US14/371,370 patent/US9944911B2/en active Active
- 2013-01-17 LT LTEP13738232.1T patent/LT2804617T/lt unknown
- 2013-01-17 EP EP13738232.1A patent/EP2804617B9/en active Active
- 2013-01-17 CA CA2861307A patent/CA2861307C/en active Active
- 2013-01-17 DK DK13738232.1T patent/DK2804617T3/da active
- 2013-01-17 PL PL13738232T patent/PL2804617T3/pl unknown
- 2013-01-17 WO PCT/US2013/021937 patent/WO2013109752A1/en active Application Filing
- 2013-01-17 ES ES13738232T patent/ES2816647T3/es active Active
- 2013-01-17 CN CN201711161230.6A patent/CN107880100A/zh active Pending
- 2013-01-17 PT PT137382321T patent/PT2804617T/pt unknown
- 2013-01-17 CN CN201380010007.5A patent/CN104136037B/zh active Active
- 2013-01-17 JP JP2014552401A patent/JP6460796B2/ja active Active
- 2013-01-17 SI SI201331779T patent/SI2804617T1/sl unknown
- 2013-01-17 HU HUE13738232A patent/HUE050875T2/hu unknown
- 2013-01-17 AU AU2013209736A patent/AU2013209736C1/en active Active
-
2015
- 2015-03-10 HK HK18112498.2A patent/HK1253217A1/zh unknown
- 2015-03-10 HK HK15102460.0A patent/HK1201757A1/xx unknown
-
2017
- 2017-07-10 JP JP2017134728A patent/JP6742279B2/ja active Active
-
2018
- 2018-03-05 US US15/912,471 patent/US11208481B2/en active Active
-
2019
- 2019-08-22 JP JP2019151758A patent/JP6783361B2/ja active Active
-
2020
- 2020-05-13 JP JP2020084303A patent/JP6918179B2/ja active Active
- 2020-08-17 HR HRP20201285TT patent/HRP20201285T1/hr unknown
- 2020-08-27 CY CY20201100807T patent/CY1123419T1/el unknown
-
2021
- 2021-07-20 JP JP2021119529A patent/JP2021176873A/ja not_active Withdrawn
- 2021-11-18 US US17/530,287 patent/US20220064293A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201285T1 (hr) | Reagensi sirp-alfa visokog afiniteta | |
| US20230039157A1 (en) | Single-chain chimeric polypeptides and uses thereof | |
| MX336623B (es) | Peptidos penetradores de las celulas y usos de los mismos. | |
| IL275497B (en) | Serum proteins with type iii fibronectin binding domains | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| SG178567A1 (en) | Affinity-matured humanized anti cea monoclonal antibodies | |
| AR086360A1 (es) | Polipeptidos anticuerpos que antagonizan cd40 | |
| BR112012033406A2 (pt) | anticorpo para diagnóstico e/ou prognóstico de câncer | |
| BRPI0607315A2 (pt) | polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma | |
| RU2012122402A (ru) | Содержащие фактор фон виллебранда (vwf) препараты и способы, наборы и применения, связанные с ними | |
| MX2019009382A (es) | Anticuerpo anti-humano de anexina a1. | |
| CN103387989A (zh) | 上皮细胞粘附分子的核酸适体EpCAM D及其制备方法 | |
| CN101556287B (zh) | 一种新型蛋白质分子量标准及其制备方法 | |
| WO2014144911A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| Bunting et al. | Novel antagonist antibody to TLR3 blocks poly (I: C)-induced inflammation in vivo and in vitro | |
| CN102977201A (zh) | 少棘蜈蚣多肽毒素mu-SLPTX-Ssm6a及其基因和应用 | |
| CN102671185A (zh) | 少棘蜈蚣多肽毒素omega-SLPTX-Ssm1a的应用 | |
| RU2017134042A (ru) | ДИМЕРЫ SCFV-FC, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ТРАНСФОРМИРУЮЩИМ ФАКТОРОМ РОСТА β1 С ВЫСОКОЙ АФФИННОСТЬЮ, АВИДНОСТЬЮ И СПЕЦИФИЧНОСТЬЮ | |
| IL209595A (en) | Isolated nucleic acid, expression vector and host cell containing it, isolated polypeptide encoded by it and chimeric polypeptide containing it, process for preparation, oligopeptide hhipl l2 mimics loop, preparations containing it and methods for its production | |
| NZ598593A (en) | A new antibiotic containing simulacrum antibody, preparation methods and application thereof | |
| CN105085646A (zh) | 蜈蚣镇痛多肽SLP_RhTx及其基因和应用 | |
| Han et al. | Preliminary investigations into surface molecularly imprinted nanoparticles for Helicobacter pylori eradication | |
| BRPI0910513B8 (pt) | uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia | |
| JPWO2020181145A5 (hr) | ||
| CN101659959B (zh) | 一种人重组角蛋白19抗原活性片段表达载体及其应用 |